Exploring Best Practices for Diagnosis and Management of Adult-Onset Stills Disease

To participate in this activity, please:

Adult-onset Still’s disease (AOSD) is a rare, polygenic autoinflammatory syndrome with a pathogenesis similar to systemic juvenile inflammatory arthritis. Join Drs. Petros Efthimiou and Olga Petryna as they discuss making the diagnosis of AOSD through interpretation of clinical and laboratory findings and careful exclusion of other diseases. The faculty review the evidence related to the variety of medications often used to treat patients with AOSD, focusing on canakinumab, the only medication approved in the United States for the disease. Case studies are utilized to share the faculty’s experience in diagnosis and treatment, so as to facilitate integration into clinical practice.

This program is also available as a podcast.  You may download it here: https://anchor.fm/aosd-podcast

Course Credit:

1.25 AMA PRA Category 1 CreditsTM
1.25 ANCC Contact Hours


Opens: 2021-06-30
Closes: 2022-06-30

Target Audience:

This activity is intended for rheumatologists, rheumatology advanced practice providers, dermatologists, primary care physicians, and other clinicians involved in the care of patients with adult-onset Still’s disease.

This activity is supported by an independent educational grant from Novartis Pharmaceutical Corporation.

    Presenting Faculty

  • Petros Efthimiou, MD, FACR

    New York Rheumatology Care, PC
    New York, New York
    Clinical Professor of Medicine
    Ross University School of Medicine
    Miramar, Florida

  • Olga Petryna, MD, FACR

    Clinical Assistant Professor
    Division of Rheumatology
    NYU Grossman School of Medicine
    New York, New York